{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:53:31Z","timestamp":1777596811711,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2006,3,24]],"date-time":"2006-03-24T00:00:00Z","timestamp":1143158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1007\/s00432-006-0090-z","type":"journal-article","created":{"date-parts":[[2006,3,23]],"date-time":"2006-03-23T10:43:08Z","timestamp":1143110588000},"page":"451-457","source":"Crossref","is-referenced-by-count":8,"title":["Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentrations"],"prefix":"10.1007","volume":"132","author":[{"given":"A.","family":"Anttonen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lepp\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Heikkil\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Grenman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Joensuu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,3,24]]},"reference":[{"key":"90_CR1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/sj.bjc.6690088","volume":"79","author":"A Anttonen","year":"1999","unstructured":"Anttonen A, Kajanti M, Heikkil\u00e4 P, Jalkanen M, Joensuu H (1999) Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer 79:558\u2013564","journal-title":"Br J Cancer"},{"key":"90_CR2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0169-5002(03)00196-X","volume":"41","author":"A Anttonen","year":"2003","unstructured":"Anttonen A, Lepp\u00e4 S, Ruotsalainen T, Alfthan H, Mattson K, Joensuu H (2003) Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 41:171\u2013177","journal-title":"Lung Cancer"},{"key":"90_CR3","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/cncr.11515","volume":"98","author":"M Barbareschi","year":"2003","unstructured":"Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD, Galligioni E, Doglioni C (2003) High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 98:474\u201383","journal-title":"Cancer"},{"key":"90_CR4","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/modpathol.3880435","volume":"14","author":"IB Bayer-Garner","year":"2001","unstructured":"Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Ownes RB, Wilson CS (2001) Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol 14:1052\u20131058","journal-title":"Mod Pathol"},{"key":"90_CR5","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1146\/annurev.biochem.68.1.729","volume":"68","author":"M Bernfield","year":"1999","unstructured":"Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M (1999) Functions of cell surface heparan sulfate proteoglygans. Annu Rev Biochem 68:729\u2013777","journal-title":"Annu Rev Biochem"},{"key":"90_CR6","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1158\/1078-0432.CCR-03-0103","volume":"10","author":"EJ Davies","year":"2004","unstructured":"Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, Slade RJ, Martin-Hirsch P, Gallagher JT , Jayson GC (2004) Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res 10:5178\u20135186","journal-title":"Clin Cancer Res"},{"key":"90_CR7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0014-5793(98)00310-X","volume":"426","author":"J-M Dore","year":"1998","unstructured":"Dore J-M, Morard F, Vita N, Wijdenes J (1998) Identification and location on syndecan-1 core protein of the epitopes of B-B2 and B-B4 monoclonal antibodies. FEBS Lett 426:67\u201370","journal-title":"FEBS Lett"},{"key":"90_CR8","doi-asserted-by":"crossref","first-page":"40764","DOI":"10.1074\/jbc.M306736200","volume":"278","author":"K Endo","year":"2003","unstructured":"Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M, Sato H (2003) Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem 278:40764\u201340770","journal-title":"J Biol Chem"},{"key":"90_CR9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R","volume":"174","author":"MS Filla","year":"1998","unstructured":"Filla MS, Dam P, Rapraeger AC (1998) The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity. J Cell Physiol 174:310\u2013321","journal-title":"J Cell Physiol"},{"key":"90_CR10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1083\/jcb.148.4.811","volume":"148","author":"ML Fitzgerald","year":"2000","unstructured":"Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M (2000) Shedding of syndecan-1 and \u20134 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 148:811\u2013824","journal-title":"J Cell Biol"},{"key":"90_CR11","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0046-8177(03)00336-8","volume":"34","author":"K Harada","year":"2003","unstructured":"Harada K, Masuda S, Hirano M, Nakanuma Y (2003) Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Hum Pathol 34:857\u2013863","journal-title":"Hum Pathol"},{"key":"90_CR12","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/sj.onc.1202002","volume":"17","author":"P Jaakkola","year":"1998","unstructured":"Jaakkola P, M\u00e4\u00e4tt\u00e4 A, Jalkanen M (1998) The activation and composition of FiRE (an FGF-inducible response element) differ in a cell type- and growth factor-specific manner. Oncogene 17:1279\u20131286","journal-title":"Oncogene"},{"key":"90_CR13","first-page":"5210","volume":"62","author":"H Joensuu","year":"2002","unstructured":"Joensuu H, Anttonen A, Eriksson M, M\u00e4kitaro R, Alfthan H, Kinnula V, Lepp\u00e4 S (2002) Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 62:5210\u20135217","journal-title":"Cancer Res"},{"key":"90_CR14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1091\/mbc.5.7.797","volume":"5","author":"CW Kim","year":"1994","unstructured":"Kim CW, Goldberger OA, Gallo RL, Bernfield M (1994) Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns. Mol Biol Cell 5:797\u2013805","journal-title":"Mol Biol Cell"},{"key":"90_CR15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/(SICI)1096-9896(1998110)186:3<300::AID-PATH180>3.0.CO;2-Q","volume":"186","author":"S Kumar-Singh","year":"1998","unstructured":"Kumar-Singh S, Jacobs W, Dhaene K, Weyn B, Bogers J, Weyler J, van Marck E (1998) Syndecan-1 expression in malignant mesothelioma: correlation with cell differentation, WT1 expression, and clinical outcome. J Pathol 186:300\u2013305","journal-title":"J Pathol"},{"key":"90_CR16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000080280","volume":"67","author":"M Leivonen","year":"2004","unstructured":"Leivonen M, Lundin J, Nordling S, von Bogulawski K, Haglung C (2004) Prognostic value of syndecan-1 expression in breast cancer. Oncology 67:11\u201318","journal-title":"Oncology"},{"key":"90_CR17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3109\/00016489709117794","volume":"117","author":"JO Pulkkinen","year":"1997","unstructured":"Pulkkinen JO, Penttinen M, Jalkanen M, Klemi P, Grenman R (1997) Syndecan-1: a new prognostic marker in laryngeal cancer. Acta Otolaryngol (Stockh) 117:312\u2013315","journal-title":"Acta Otolaryngol (Stockh)"},{"key":"90_CR18","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1016\/S0021-9258(18)32712-1","volume":"258","author":"A Rapraeger","year":"1983","unstructured":"Rapraeger A, Bernfield M (1983) Heparan sulfate proteoglycans from mouse mammary epithelial cells. A putative proteoglycan associates quantitatively with lipid vessels. J Biol Chem 258:3632\u20133636","journal-title":"J Biol Chem"},{"key":"90_CR19","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1182\/blood.V94.10.3334.422k18_3334_3339","volume":"94","author":"P Salven","year":"1999","unstructured":"Salven P, Teerenhovi L, Joensuu H (1999) A high pretreatment serum basic fibroblast growth factor concentration is independent predictor of poor prognosis in non-Hodgkin\u2019s lymphoma. Blood 94:3334\u20133339","journal-title":"Blood"},{"key":"90_CR20","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood.V96.9.3139","volume":"96","author":"C Seidel","year":"2000a","unstructured":"Seidel C, Borset M, Hjertner O, Cao D, Abildgaard N, Hjort-Hansen H, Sanderson RD, Waage A, Sundan A (2000a) High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 96:3139\u20133146","journal-title":"Blood"},{"key":"90_CR21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood.V95.2.388","volume":"95","author":"C Seidel","year":"2000b","unstructured":"Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IMS, Abildgaard N, Waage A, Borset M (2000b) Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95:388\u2013392","journal-title":"Blood"},{"key":"90_CR22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/01.TP.0000074316.76104.A5","volume":"76","author":"C Seidel","year":"2003","unstructured":"Seidel C, Ringden O, Remberger M (2003) Increased levels of syndecan-1 in serum during acute graft-versus-host disease. Transplantation 76:423\u2013426","journal-title":"Transplantation"},{"key":"90_CR23","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/cncr.20542","volume":"101","author":"L Shah","year":"2004","unstructured":"Shah L, Walter KL, Borczuk AC, Kawut SM, Sonett JR, Gorenstein L, Ginsburg ME, Steinglass KM, Powell CA (2004) Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer 101:1632\u20131638","journal-title":"Cancer"},{"key":"90_CR24","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1073\/pnas.91.8.3334","volume":"91","author":"J Spring","year":"1994","unstructured":"Spring J, Paine-Saunders SE, Hynes RO, Bernfield M (1994) Drosophila syndecan: conservation of cell-surface heparan sulfate proteoglycan. Proc Natl Acad Sci USA 91:3334\u20133338","journal-title":"Proc Natl Acad Sci USA"},{"key":"90_CR25","doi-asserted-by":"crossref","first-page":"24417","DOI":"10.1074\/jbc.274.34.24417","volume":"274","author":"R Volk","year":"1999","unstructured":"Volk R, Schwartz JJ, Li J, Rosenberg RD, Simons M (1999) The role of syndecan cytoplasmic domain in basic fibroblast growth factor-dependent signal transduction. J Biol Chem 274:24417\u201324424","journal-title":"J Biol Chem"},{"key":"90_CR26","first-page":"4905","volume":"20","author":"JP Wiksten","year":"2000","unstructured":"Wiksten JP, Lundin J, Norling S, Kokkola A, Haglund C (2000) A prognostic value of syndecan-1 in gastric cancer. Anticancer Res 20:4905\u20134908","journal-title":"Anticancer Res"},{"key":"90_CR27","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood.V100.2.610","volume":"100","author":"Y Yang","year":"2002","unstructured":"Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, Epstein J, Sanderson RD (2002) Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 100:610\u2013617","journal-title":"Blood"},{"key":"90_CR28","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/blood-2003-09-3334","volume":"104","author":"K Yuan","year":"2004","unstructured":"Yuan K, Hong TM, Chen JJ, Tsai WH, Lin MT (2004) Syndecan-1 upregulated by ephrinB2\/EphB4 plays dual roles in inflammatory angiogenesis. Blood 104:1025\u20131033","journal-title":"Blood"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-006-0090-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-006-0090-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-006-0090-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T03:50:24Z","timestamp":1627185024000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-006-0090-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,24]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["90"],"URL":"https:\/\/doi.org\/10.1007\/s00432-006-0090-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,24]]}}}